200 related articles for article (PubMed ID: 17944832)
1. Crystal structure of the Leishmania major phosphodiesterase LmjPDEB1 and insight into the design of the parasite-selective inhibitors.
Wang H; Yan Z; Geng J; Kunz S; Seebeck T; Ke H
Mol Microbiol; 2007 Nov; 66(4):1029-38. PubMed ID: 17944832
[TBL] [Abstract][Full Text] [Related]
2. Cyclic nucleotide specific phosphodiesterases of Leishmania major.
Johner A; Kunz S; Linder M; Shakur Y; Seebeck T
BMC Microbiol; 2006 Mar; 6():25. PubMed ID: 16522215
[TBL] [Abstract][Full Text] [Related]
3. Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-1-methylxanthine suggest a conformation determinant of inhibitor selectivity.
Huai Q; Liu Y; Francis SH; Corbin JD; Ke H
J Biol Chem; 2004 Mar; 279(13):13095-101. PubMed ID: 14668322
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase inhibitors as a new generation of antiprotozoan drugs: exploiting the benefit of enzymes that are highly conserved between host and parasite.
Seebeck T; Sterk GJ; Ke H
Future Med Chem; 2011 Aug; 3(10):1289-306. PubMed ID: 21859303
[TBL] [Abstract][Full Text] [Related]
5. A Unique Sub-Pocket for Improvement of Selectivity of Phosphodiesterase Inhibitors in CNS.
Wang Y; Ke H
Adv Neurobiol; 2017; 17():463-471. PubMed ID: 28956343
[TBL] [Abstract][Full Text] [Related]
6. Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and Implications for design of parasite selective inhibitors.
Wang H; Kunz S; Chen G; Seebeck T; Wan Y; Robinson H; Martinelli S; Ke H
J Biol Chem; 2012 Apr; 287(15):11788-97. PubMed ID: 22356915
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for the activity of drugs that inhibit phosphodiesterases.
Card GL; England BP; Suzuki Y; Fong D; Powell B; Lee B; Luu C; Tabrizizad M; Gillette S; Ibrahim PN; Artis DR; Bollag G; Milburn MV; Kim SH; Schlessinger J; Zhang KY
Structure; 2004 Dec; 12(12):2233-47. PubMed ID: 15576036
[TBL] [Abstract][Full Text] [Related]
8. Homology modeling, docking studies and molecular dynamic simulations using graphical processing unit architecture to probe the type-11 phosphodiesterase catalytic site: a computational approach for the rational design of selective inhibitors.
Cichero E; D'Ursi P; Moscatelli M; Bruno O; Orro A; Rotolo C; Milanesi L; Fossa P
Chem Biol Drug Des; 2013 Dec; 82(6):718-31. PubMed ID: 23865680
[TBL] [Abstract][Full Text] [Related]
9. Kinetic and structural studies of phosphodiesterase-8A and implication on the inhibitor selectivity.
Wang H; Yan Z; Yang S; Cai J; Robinson H; Ke H
Biochemistry; 2008 Dec; 47(48):12760-8. PubMed ID: 18983167
[TBL] [Abstract][Full Text] [Related]
10. Multiple elements jointly determine inhibitor selectivity of cyclic nucleotide phosphodiesterases 4 and 7.
Wang H; Liu Y; Chen Y; Robinson H; Ke H
J Biol Chem; 2005 Sep; 280(35):30949-55. PubMed ID: 15994308
[TBL] [Abstract][Full Text] [Related]
11. Cyclic Nucleotide-Specific Phosphodiesterases as Potential Drug Targets for Anti-Leishmania Therapy.
Sebastián-Pérez V; Hendrickx S; Munday JC; Kalejaiye T; Martínez A; Campillo NE; de Koning H; Caljon G; Maes L; Gil C
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30104270
[TBL] [Abstract][Full Text] [Related]
12. Interactions between cyclic nucleotide phosphodiesterase 11 catalytic site and substrates or tadalafil and role of a critical Gln-869 hydrogen bond.
Weeks JL; Corbin JD; Francis SH
J Pharmacol Exp Ther; 2009 Oct; 331(1):133-41. PubMed ID: 19641165
[TBL] [Abstract][Full Text] [Related]
13. Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity.
Ke H; Wang H
Curr Top Med Chem; 2007; 7(4):391-403. PubMed ID: 17305581
[TBL] [Abstract][Full Text] [Related]
14. A substrate selectivity and inhibitor design lesson from the PDE10-cAMP crystal structure: a computational study.
Lau JK; Li XB; Cheng YK
J Phys Chem B; 2010 Apr; 114(15):5154-60. PubMed ID: 20349929
[TBL] [Abstract][Full Text] [Related]
15. Characterization of TbPDE2A, a novel cyclic nucleotide-specific phosphodiesterase from the protozoan parasite Trypanosoma brucei.
Zoraghi R; Kunz S; Gong K; Seebeck T
J Biol Chem; 2001 Apr; 276(15):11559-66. PubMed ID: 11134002
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase inhibitors: factors that influence potency, selectivity, and action.
Francis SH; Houslay MD; Conti M
Handb Exp Pharmacol; 2011; (204):47-84. PubMed ID: 21695635
[TBL] [Abstract][Full Text] [Related]
17. Cloning and characterization of a cAMP-specific phosphodiesterase (TbPDE2B) from Trypanosoma brucei.
Rascón A; Soderling SH; Schaefer JB; Beavo JA
Proc Natl Acad Sci U S A; 2002 Apr; 99(7):4714-9. PubMed ID: 11930017
[TBL] [Abstract][Full Text] [Related]
18. Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors.
Zoraghi R; Francis SH; Corbin JD
Biochemistry; 2007 Nov; 46(47):13554-63. PubMed ID: 17979301
[TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterase-5 Gln817 is critical for cGMP, vardenafil, or sildenafil affinity: its orientation impacts cGMP but not cAMP affinity.
Zoraghi R; Corbin JD; Francis SH
J Biol Chem; 2006 Mar; 281(9):5553-8. PubMed ID: 16407275
[TBL] [Abstract][Full Text] [Related]
20. PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.
Jansen C; Kooistra AJ; Kanev GK; Leurs R; de Esch IJ; de Graaf C
J Med Chem; 2016 Aug; 59(15):7029-65. PubMed ID: 26908025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
